Lung Cancer Diagnostic And Screening Market Report 2026

Lung Cancer Diagnostic And Screening Market Overview

• Lung Cancer Diagnostic And Screening market size has reached to $2.56 billion in 2025 • Expected to grow to $4.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Surging Prevalence Of Lung Cancer Drives Expansion In The Lung Cancer Diagnostic And Screening Market • Market Trend: Blood-Based Test To Provide Accessible And Convenient Lung Cancer Screening • North America was the largest region in 2025.

What Is Covered Under Lung Cancer Diagnostic And Screening Market?

Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma. The main products of lung cancer diagnostics and screening are instruments, consumables, and accessories. An instrument refers to products that are used to read or analyze the results of a diagnostic product, and process samples for a diagnostic product. The various tests include biomarkers tests, imaging tests, biopsy, blood tests, and others used for various cancer types such as non-small cell lung cancer, and small cell lung cancer. These are used by various end-users such as hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

What Is The Lung Cancer Diagnostic And Screening Market Growth Forecast?

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $4.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to expansion of national lung cancer screening initiatives, increasing adoption of low-dose ct screening, growing demand for biomarker and blood-based tests, rising healthcare investments in oncology diagnostics, improved access to diagnostic imaging centers. Major trends in the forecast period include rising adoption of early lung cancer screening programs, growing use of advanced imaging and biomarker tests, increasing focus on high-risk population screening, expansion of non-invasive diagnostic techniques, rising integration of multimodal diagnostic pathways.

Global Lung Cancer Diagnostic And Screening Market Segmentation

1) By Product: Instruments, Consumables And Accessories 2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests 3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer 4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users Subsegments: 1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems 2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

What Is The Driver Of The Lung Cancer Diagnostic And Screening Market?

The increasing prevalence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market going forward. Lung cancer is a malignant disease with symptoms such as coughing, chest pain, and difficulty breathing that is defined by the unchecked proliferation of abnormal cells in the lung tissues. Lung cancer diagnosis and screening help lung cancer patients early diagnose the disease with various tests, including an incisional biopsy and a bronchoscopy. For instance, in January 2023, according to the American Cancer Society, a US-based government organization, in the United States, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women). Further, there were reportedly 127,070 deaths from lung cancer (67,160 in men and 59,910 in women). Therefore, the rise in the prevalence of lung cancer is driving the growth of the lung cancer diagnostic and screening industry.

Key Players In The Global Lung Cancer Diagnostic And Screening Market

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Global Lung Cancer Diagnostic And Screening Market Trends and Insights

Major companies in the lung cancer diagnostic and screening market are focused on developing a blood-based test that utilizes machine learning, such as whole-genome machine learning, to provide accessible and convenient lung cancer screening and gain a competitive edge in the market. Whole-genome machine learning refers to the application of machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism's entire genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, launched FirstLook Lung, a blood test using whole-genome machine learning to analyze cell-free DNA fragments, enhancing lung cancer screening with a 99.7% NPV. The test, designed for routine blood work, identifies individuals with potential lung cancer, including early-stage disease. Addressing low LDCT screening uptake, the test aims to improve population health.

What Are Latest Mergers And Acquisitions In The Lung Cancer Diagnostic And Screening Market?

In May 2025, Johnson & Johnson MedTech, the medical-technology division of Johnson & Johnson Private Limited, partnered with Qure.ai, an India-based artificial intelligence healthcare company, to enhance early detection of lung cancer in India through AI-powered screening. With this partnership, Johnson & Johnson MedTech and Qure.ai aim to deploy Qure.ai’s AI-driven imaging solutions across a network of hospitals to enable earlier detection of lung cancer nodules, improving chances of timely treatment and better patient outcomes. Qure.ai is an India-based company specializing in artificial-intelligence diagnostic tools for radiology and medical imaging.

Regional Outlook

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lung Cancer Diagnostic And Screening Market?

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lung Cancer Diagnostic And Screening Market Report 2026?

The lung cancer diagnostic and screening market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostic and screening industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.